Key Segmentation
By Type
-
Automated
-
Semi-Automated
-
Manual
By Product
-
Automated Workstations
-
Pipettes
-
Dispensers
-
Consumables
-
Others
By Application
-
Drug Discovery
-
Cell and Gene Therapy
-
Clinical Diagnostics
-
Genomics and Proteomics
-
Others
By End User
-
Pharmaceutical and Biotechnology Companies
-
CROs and CMOs
-
Academic and Research Institutes
-
Clinical Laboratories
-
Others
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Tecan Group, Hamilton Company, Beckman Coulter Life Sciences, Thermo Fisher Scientific, Eppendorf, Agilent Technologies, Revvity, Mettler-Toledo, Gilson, Opentrons, SPT Labtech, Analytik Jena, INTEGRA Biosciences, BRAND, DISPENDIX and Formulatrix.
Key opportunities include benchtop automation for smaller laboratories, validated workflows for genomics, cell and gene therapy manufacturing, and compliance-ready software.
Rising drug discovery investment and sequencing workloads, together with the need for accurate, reproducible sample handling, are the main growth factors.
By Type, the Automated segment dominated the market in 2025 with an estimated 48.73% share, supported by demand for consistent results at high sample volumes.
North America dominated the market with a share of 41.25% in 2025, driven by a dense base of drug developers, genomics companies and research universities.